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Abstract 31 
A mature national joint registry with widespread adoption and audit can successfully demonstrate 32 
trends and influence future orthopaedic practice.  Correlations can be identified; however, this 33 
should not be misinterpreted as causality.  It is essential to consider confounding when analysing 34 
observational data sets. 35 
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This commentary serves to discuss what we have learnt from a mature national joint registry, its 61 
influence on orthopaedic practice, but also the limitations of observational data sets. 62 
Outcomes have been measured as early as the earliest total hip arthroplasty (THA).  Reporting on 63 
the Wiles THA in 1938 [1], which utilized screw fixation and a metal on metal head, “there was a 64 
measure of success in that those who were previously bed-ridden were thereby enabled just to 65 
walk.” It was documented that “she had 20⁰ of active flexion.”  “The radiographs of their hips were 66 
destroyed during the war, not by enemy action but deliberately by those responsible for the care of 67 
hospital records.” Not only does this highlight the low expectations at the time but the need for 68 
outcome data to be recorded independent of the surgeon or hospital. 69 
Approximately 160,000 THA and total knee arthroplasty (TKA) procedures are performed in England 70 
and Wales each year. In the United States (US), more than one million THA and TKA are performed 71 
annually [2, 3], with over 7.2 million currently in-situ in the general population [4]. Arthroplasty 72 
datasets are widely used at surgeon, hospital, hospital owner [5], national [6] and international [7] 73 
level. National arthroplasty registries are utilised by many countries such as Denmark, Norway, 74 
Sweden, Catalonia, Portugal, Australia, New Zealand, and Canada. 75 
The National Joint Registry (NJR) of England, Wales, Northern Ireland and the Isle of Man was 76 
created in 2003 to identify implants with high failure rates, and is currently the largest registry, with 77 
more than 2.1 million entries [I]. More than 800,000 primary hip arthroplasties and 90,000 revision 78 
hip arthroplasties are recorded in the NJR. It is broadly adopted with over 95% of primary THAs 79 
entered into the registry.  Since 2006, using revision data, the percentage of cases that can be linked 80 
to the primary arthroplasty has increased [8]. A number of external studies have investigated the 81 
validity of data within the NJR [8, 9]. 82 
In comparison, the American Joint Replacement Registry (AJRR) is in its infancy. Since its inception in 83 
2010, it has documented approximately ~550,000 joint arthroplasties, only representing 7-8% of 84 
those implanted [6]. 85 
The NJR [10] has been able to show the trends in fixation, bearing surfaces, demographics and 86 
complications. 87 
Fixation 88 
The changing use of implant fixation has been documented and observed. Figure 1.  There was a 89 
steady fall in cemented fixation between 2003 and 2009 where levels have plateaued at 30%. 90 
 Uncemented fixation remains the most popular at 39% but there has been a steady increase in 91 
hybrid fixation from 2010 to 26%. 92 
Bearing Surfaces 93 
Trends in selection of bearing surfaces for uncemented primary hip arthroplasties have shown 94 
marked fluctuations. Figure 2.  Metal-on-metal (MoM) bearings increased in popularity from 2003, 95 
peaking in 2007 at 30% usage.   There was a sharp decline from 2008 to 2011 where it has remained 96 
at 1%.  This decline coincided with more favourable use of ceramic-on-ceramic (CoC) and ceramic-97 
on-polyethylene (CoP) bearings. Metal-on-polyethylene (MoP) has consistently remained a widely 98 
used bearing surface, currently the most popular at 40% usage. 99 
The trends in bearing surface utilisation on the NJR reflects known changes in practice such as the 100 
decline of MoM hips in 2007 following widespread concern in the orthopaedic community  and the 101 
re-adoption of polyethylene bearings with use of highly cross linked polyethylene. The increased use 102 
of ceramic femoral heads maybe due to concerns regarding taperosis and higher patient demands in 103 
both the UK and USA. 104 
Revision Rates 105 
The emergence of highly cross linked polyethylene has seen a dramatic reduction in revision rate for 106 
loosening. In contrast to MoM, the revision data up to 15 years confirms that this innovation has 107 
worked.  [11] Figure 3.  MoM bearing surfaces have overall poorer outcomes, with 12-year revision 108 
rates of 20% compared to <5% for all other bearing surfaces. Overall cumulative revision rate follows 109 
a linear progression, after an initial spike within 3 months consistent with early complications such 110 
as dislocation, infection and fracture. When compared to primary arthroplasty surgery, revision 111 
arthroplasty have a higher failure rate nearing 15% at 10 years. 112 
The risk of re-revision was examined in patients who required revision surgery of their primary 113 
arthroplasty. Two groups were compared; those with primary arthroplasty listed on the NJR and 114 
those without. This comparison demonstrated that those listed on the NJR had a significantly higher 115 
10-year re-revision rate. Those listed on the NJR are likely to have had their primary surgery after 116 
2003, and therefore earlier failure.  Observation of these trends demonstrates that early failure 117 
significantly increases the risk of re-revision.  A review of multiple joint registries reported that 30-118 
50% of arthroplasty failures occurred in the first one to two years[12] suggesting catastrophic failure 119 
due to sepsis, gross malpositioning, dislocation or fracture.  This stresses the importance of getting it 120 
right the first time [13]. 121 
Demographic Outcomes 122 
The UK National Institute of Clinical Excellence Guidelines [14] suggest that 95% of hip replacements 123 
should last at least 10 years. Review of the NJR [10]indicates that only males over 75 and females 124 
over 65 achieve this threshold.  Figure 4.  Generally younger patients have a higher revision rate and 125 
women in particular do poorly, with a 10-year revision rate in the under 55s of over 12.5%. The 126 
higher revision rates for females undergoing MoM identified using NJR data has been used to 127 
change practice [10] and policy [15] to the extent that in 2013 almost 99% of hip resurfacings were 128 
performed in men only. If MoM hips are excluded, the revision risk is slightly greater in males than 129 
females at around 5% at 10 years in those <55 years old.  Figure 5. 130 
The underlying aetiology of hip disease requiring THA in younger patients may explain the higher 131 
revision rate.  Corrected or uncorrected dysplasia, adaptive gait patterns, abnormal version and 132 
offset may result in an unfavourable biomechanical environment compared to osteoarthritis in the 133 
elderly.  Higher activity levels and expectations further compound arthroplasty in the younger 134 
patient.  135 
Linking Databases 136 
Linking good quality databases enables investigators to answer complex questions.  Case reports and 137 
basic science data commented that the release of metal ions from metal on metal hip replacement 138 
and from taperosis is carcinogenic and that patients with these devices may increase a patient's 139 
cancer risk. [16] 140 
Smith et al [17] using (Hospital Episode Statistics) (HES) data concluded that compared to an age and 141 
sex matched population, patients who have a total hip replacement, have a lower incidence of 142 
cancer (1.25% vs 1.65%).  Resurfacing MoM procedures were less likely to get a diagnosis of any 143 
cancer and a lower risk of death than any other bearing surface. 144 
The risk ratio of heart failure, cancer and mortality were 0.389, 0.624 and 0.389 respectively in 145 
patients who underwent MoM hip arthroplasty compared with controls. [17] 146 
 147 
Confounding 148 
There is a danger of using large observational data series to make erroneous conclusions. 149 
 Correlations can be identified but causation cannot be concluded.   For example, ‘people with grey 150 
hair have a higher risk of cancer’ therefore ‘grey hair causes cancer’.  Clearly these statements hold 151 
no scientific merit but misinterpreting observational data is commonplace, particularly to make 152 
headlines in the lay press.   153 
It is a valid observation that patients taking anti-epileptics have a 50 times greater risk of having a 154 
seizure than a matched population.   Figure 6.  They are confounded by their indication [18]There is 155 
a four times risk of dying in the three months following stopping a statin.  The risks and benefits of 156 
statins extend beyond the scope of an orthopaedic readership but why would a physician stop a low 157 
risk preventative medication?  Figure 7.  This observation is confounded by patients being placed on 158 
a palliative care pathway for terminal illness.   Similarly the risk of rheumatoid arthritis is five times 159 
greater in NSAID takers and the risk of being hospitalised with pneumonia is nine times higher in 160 
patients prescribed amoxicillin.   On a lighter note, if you have seen a doctor, the risk of dying within 161 
the next two weeks is 30 times higher!  Table 1. 162 
There is always some confounding and when analysing observational data it is important to consider 163 
this especially if the authors are biased towards an exciting headline.   164 
Orthopaedic data comparison is often age matched but within our scope of practise we see 70 year 165 
olds running marathons and 50 year olds walking 10 yards with a Zimmer frame.  Patient expectation 166 
is multifactorial and can not be easily statistically controlled for.  Revision rate particularly of an 167 
implant perceived to be easily revised may be increased, not because it is mechanically inferior or 168 
defective but because its indication is in high functioning, high demand patients.  However this 169 
rationale was used by metal on metal hip manufacturers to defend a product which we subsequently 170 
know has design concerns. 171 
Conclusion 172 
In summary, registry data and large datasets can be an asset to arthroplasty surgeons, 173 
manufacturers and policy makers to identify trends and outcomes.  The NJR is successful due to 174 
widespread adoption and auditing to ensure high quality, representative data is reported.   175 
Analysis of the NJR has highlighted that total hip arthroplasty in young patients lags behind surgeons 176 
and policy maker’s expectations.  The choice of bearing surface, fixation technique and role of 177 
centralisation of this complex subgroup continues to be debated. This may be an opportunity to use 178 
technology to improve outcome to meet an unmet need.  The rate of re-revision is greater if the 179 
revision occurred closer to the primary arthroplasty suggesting revision for indications other than 180 
aseptic loosening are less likely to be successful.   181 
Big data can be very powerful. [19]  Linking databases can answer complex questions across a range 182 
of conditions than a single database.  However, small data-sets, data mining and over interpretation 183 
can result in incorrect conclusions.  Observational data may demonstrate a correlation but does not 184 
prove causality.  It is important to critically analyse the population characteristics, complexity and 185 
risk factors for outcomes.  It is beholden on us all who interpret large observational datasets to make 186 
sure they have considered confounding. 187 
 188 
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Figures 274 
Figure 1.  Fixation method used in primary hip replacements. [10] 275 
 276 
 277 
Figure 2.  Bearing Surface used in uncemented primary hip replacements. [10] 278 
 279 
 280 
Figure 3.  Comparison of revision data comparing cross-linked versus non cross-linked polyethylene. 281 
[11] 282 
 283 
 284 
 285 
Figure 4.  Revision Rate by age group comparing males and females.  [10]286 
 287 
Figure 5.  Revision Rate, excluding metal on metal, by age group comparing males and females. [10]288 
 289 
 290 
Figure 6.  Health outcomes are confounded by indication for intervention. 291 
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 297 
 298 
Figure 7.   299 
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 304 
 305 
Health intervention Health outcome 
Risk of the 
outcome  
Statin Heart attack 
High risk of heart 
attack 
Table 1.  Risk of outcome confounded by indication. 306 
Intervention Outcome Risk 
Anti-epileptics Seizure 50x 
NSAIDS Rheumatoid Arthritis 5x 
Amoxicillin Hospitalization Pneumonia 9x 
Stopping statins Death within 3 months 4x 
Seeing a doctor Death within 2 weeks 30x 
 307 
